These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 33423452)

  • 1. Assessment of eosinophilic nasal inflammation in patients with severe asthma and nasal polyposis before and after six months of therapy with Benralizumab.
    Buonamico E; Dragonieri S; Sciancalepore PI; Carratù P; Carpagnano GE; Resta O; Gelardi M
    J Biol Regul Homeost Agents; 2020; 34(6):2353-2357. PubMed ID: 33423452
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
    Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
    Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence of eosinophilic inflammation and worsening asthma symptoms between doses of benralizumab.
    Cormier M; Cartier A
    J Allergy Clin Immunol Pract; 2020; 8(10):3605-3607. PubMed ID: 32603903
    [No Abstract]   [Full Text] [Related]  

  • 4. Benralizumab: an updated treatment of eosinophilic asthma.
    Cushen B; Menzies-Gow A
    Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
    Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
    J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
    Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
    Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
    Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Benralizumab in Severe Eosinophilic Asthma Under Conditions of Routine Clinical Practice.
    Miralles López JC; Andújar-Espinosa R; Bravo-Gutiérrez FJ; Castilla-Martínez M; Flores-Martín I; Alemany-Francés ML; Pajarón-Fernández MJ; Mora González A; Valverde-Molina J; Pérez-Fernández V;
    J Investig Allergol Clin Immunol; 2022 Jun; 32(3):220-223. PubMed ID: 35166673
    [No Abstract]   [Full Text] [Related]  

  • 11. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma.
    d'Ancona G; Kavanagh JE; Dhariwal J; Hearn AP; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Jackson DJ; Kent BD
    Allergy; 2021 Jul; 76(7):2238-2241. PubMed ID: 33432682
    [No Abstract]   [Full Text] [Related]  

  • 13. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
    Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
    Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy.
    Howarth P; Chupp G; Nelsen LM; Bradford ES; Bratton DJ; Smith SG; Albers FC; Brusselle G; Bachert C
    J Allergy Clin Immunol; 2020 Jun; 145(6):1713-1715. PubMed ID: 32084443
    [No Abstract]   [Full Text] [Related]  

  • 16. Benralizumab in Real Life.
    Miralles López JC; Escudero Pastor AI; Carbonell Martínez A; Navarro Garrido C; Bonilla Pacheco Y; Petrik Petrik Y
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):87-88. PubMed ID: 32573458
    [No Abstract]   [Full Text] [Related]  

  • 17. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
    Dávila González I; Moreno Benítez F; Quirce S
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial comment on "Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)".
    Cabrera-Perez JS; Eigenmann P; Akenroye A
    Pediatr Allergy Immunol; 2024 Apr; 35(4):e14128. PubMed ID: 38646955
    [No Abstract]   [Full Text] [Related]  

  • 19. Benralizumab for the treatment of asthma.
    Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
    Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
    Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.